Related Experiment Video
Updated: Jun 22, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Established and newly proposed mechanisms of chronic cyclosporine nephropathy
1Division of Nephrology, Transplantation research center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seocho-gu, Seoul, Korea.
Insights
Cyclosporine (CsA) effectively treats transplant rejection and autoimmune diseases but can cause kidney damage. This review explores CsA nephropathy mechanisms and preventive strategies to mitigate renal injury.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Cyclosporine (CsA) is vital for solid-organ transplantation and autoimmune disease management.
- CsA use is limited by significant acute and chronic nephropathy, posing a major clinical challenge.
- Acute CsA nephropathy involves reduced renal blood flow, while chronic mechanisms are complex.
Purpose of the Study:
- To review current understanding of CsA-induced nephropathy.
- To explore the multifaceted mechanisms underlying chronic CsA nephropathy.
- To discuss preventive strategies for CsA-related renal injury.
Main Methods:
- This review synthesizes existing literature on CsA nephropathy.
- It examines implicated molecular and cellular pathways.
- It discusses therapeutic interventions and preventative measures.
Main Results:
- Chronic CsA nephropathy involves complex pathways including the renin-angiotensin system (RAS), endothelin-1, nitric oxide (NO) dysregulation, TGF-beta1 up-regulation, apoptosis, inflammation, and endoplasmic reticulum stress.
- Dosage reduction and specific renoprotective agents may ameliorate CsA-induced renal injury.
Conclusions:
- Understanding the diverse mechanisms of CsA nephropathy is crucial for effective management.
- Preventive strategies, including dosage adjustment and adjunctive therapies, are essential to minimize renal damage.
- Further research into CsA nephropathy pathogenesis can lead to improved patient outcomes.
Abstract:
Cyclosporine (CsA) has improved patient and graft survival rates following solid-organ transplantation and has shown significant clinical benefits in the management of autoimmune diseases. However, the clinical use of CsA is often limited by acute or chronic nephropathy, which remains a major problem. Acute nephropathy depends on the dosage of CsA and appears to be caused by a reduction in renal blood flow related to afferent arteriolar vasoconstriction. However, the mechanisms underlying chronic CsA nephropathy are not completely understood. Activation of the intrarenal renin-angiotensin system (RAS), increased release of endothelin-1, dysregulation of nitric oxide (NO) and NO synthase, up-regulation of transforming growth factor-beta1 (TGF-beta1), inappropriate apoptosis, stimulation of inflammatory mediators, enhanced innate immunity, endoplasmic reticulum stress, and autophagy have all been implicated in the pathogenesis of chronic CsA nephropathy. Reducing the CsA dosage or using other renoprotective drugs (angiotensin II receptor antagonist, mycophenolate mofetil, and statins, etc.) may ameliorate chronic CsA-induced renal injury. This review discusses old and new concepts in CsA nephropathy and preventive strategies for this clinical dilemma.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Diabetic Nephropathy
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease III: Interprofessional Care
Chronic Inflammation: Introduction
